English

INTEGRATED BIOPHARMA INC

EDGAR

INBP Annual report (10-K) · filed 2026-09-25

130 filing records in this dataset, filed from 1996-12-09 to 2026-09-25. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

10.3 million iso4217-usd

2019 Q1 · iso4217-usd

Exact inputs and evidence

Revenue: 10304000 iso4217-usd Source

Cash and cash equivalents: 4.47 million USD 2026-06-30 Source
Exact value

4471000 USD
Long-term debt including current maturities: 0 USD 2023-06-30 Source
Exact value

0 USD
Shares outstanding: 31.1 million shares 2026-06-30 Source
Exact value

31059610 shares

Reported share-count change

0.00% · 0 shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

31059610 shares · 2025-06-30· Source
31059610 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

44.2 million iso4217-usd

2017-10-01 – 2018-09-30

Exact inputs and evidence

Revenue: 10800000 iso4217-usd · 2017-10-01 – 2017-12-31 Source
Revenue: 10575000 iso4217-usd · 2018-01-01 – 2018-03-31 Source
Revenue: 43710000 iso4217-usd · 2017-07-01 – 2018-06-30 Source
Revenue: 31145000 iso4217-usd · 2017-07-01 – 2018-03-31 Source
Revenue: 10304000 iso4217-usd · 2018-07-01 – 2018-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-09-25.

Financial data available through: 2026-06-30.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2018-06-30
Operating income: 6 of 11 periods available· newest 2026-06-30
Net income: 6 of 11 periods available· newest 2026-06-30
Operating cash flow: 6 of 11 periods available· newest 2026-06-30
Capital expenditure: 6 of 11 periods available· newest 2026-06-30
Total assets: 6 of 11 periods available· newest 2026-06-30
Total liabilities: 6 of 11 periods available· newest 2026-06-30
Current assets: 6 of 11 periods available· newest 2026-06-30
Current liabilities: 6 of 11 periods available· newest 2026-06-30
Cash and cash equivalents: 6 of 11 periods available· newest 2026-06-30
Long-term debt including current maturities: 3 of 11 periods available· newest 2023-06-30
Shares outstanding: 6 of 11 periods available· newest 2026-06-30

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
-451.7%

Prior period

USD 808,000

2024-07-01 – 2025-06-30
Current period

−USD 2.84 million

2025-07-01 – 2026-06-30

Exact inputs and evidence

-2842000 − 808000 = -3650000 USD

808000 USD · 2024-07-01 – 2025-06-30
Inspect prior input Prior source
-2842000 USD · 2025-07-01 – 2026-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · INTEGRATED BIOPHARMA INC · 2026-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Year-over-year change in Net income: -3650000 USD Concept: fundies:NetIncome Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -2842000 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm#624092 Filing: 000143774926031241 Input fundies:NetIncome: 808000 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm#624774 Filing: 000143774926031241
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-39.9%

Prior period

USD 2.07 million

2024-07-01 – 2025-06-30
Current period

USD 1.24 million

2025-07-01 – 2026-06-30

Exact inputs and evidence

1241000 − 2065000 = -824000 USD

2065000 USD · 2024-07-01 – 2025-06-30
Inspect prior input Prior source
1241000 USD · 2025-07-01 – 2026-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · INTEGRATED BIOPHARMA INC · 2026-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Year-over-year change in Operating cash flow: -824000 USD Concept: fundies:OperatingCashFlow Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 1241000 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm#655977 Filing: 000143774926031241 Input fundies:OperatingCashFlow: 2065000 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm#656770 Filing: 000143774926031241
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+81.2%

Prior period

USD 191,000

2024-07-01 – 2025-06-30
Current period

USD 346,000

2025-07-01 – 2026-06-30

Exact inputs and evidence

346000 − 191000 = 155000 USD

191000 USD · 2024-07-01 – 2025-06-30
Inspect prior input Prior source
346000 USD · 2025-07-01 – 2026-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · INTEGRATED BIOPHARMA INC · 2026-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Year-over-year change in Capital expenditure: 155000 USD Concept: fundies:CapitalExpenditure Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 346000 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm#660132 Filing: 000143774926031241 Input fundies:CapitalExpenditure: 191000 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm#660820 Filing: 000143774926031241
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2018 2017-07-01 – 2018-06-30

Revenue iso4217-usd 43.71 million 100% of revenue
Operating costs Derived Unavailable An input is unavailable.
Operating income Unavailable An input is unavailable.
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow Unavailable An input is unavailable.
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.
2018 Not shown: operating income or net income is not reported.
2018 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2015-07-01 – 2016-06-30	42214000	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2015-07-01 – 2016-06-30: 42214000 iso4217-usd Inspect Revenue Open source
2017 2016-04-01 – 2017-03-31	35707000	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2016-04-01 – 2017-03-31: 35707000 iso4217-usd Inspect Revenue Open source
2017 2016-07-01 – 2017-06-30	46954000	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2016-07-01 – 2017-06-30: 46954000 iso4217-usd Inspect Revenue Open source
2018 2017-04-01 – 2018-03-31	31145000	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2017-04-01 – 2018-03-31: 31145000 iso4217-usd Inspect Revenue Open source
2018 2017-07-01 – 2018-06-30	43710000	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2017-07-01 – 2018-06-30: 43710000 iso4217-usd Inspect Revenue Open source

Amounts are exact, in iso4217-usd.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

iso4217-usd 43.7M 2018

Values and sources

Revenue values and source evidence
Period	Series	Value(iso4217-usd)	Source evidence
20162016-06-30	Revenue	42214000	Revenue: 42214000 Open source
20172017-03-31	Revenue	35707000	Revenue: 35707000 Open source
20172017-06-30	Revenue	46954000	Revenue: 46954000 Open source
20182018-03-31	Revenue	31145000	Revenue: 31145000 Open source
20182018-06-30	Revenue	43710000	Revenue: 43710000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-6.9% 2018

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-06-30	Year over year	No prior comparable period	Revenue: 42214000 Open source
20172017-03-31	Year over year	No prior comparable period	Revenue: 35707000 Open source
20172017-06-30	Year over year	11.2%	Revenue: 46954000 Open source Revenue: 42214000 Open source
20182018-03-31	Year over year	-12.8%	Revenue: 31145000 Open source Revenue: 35707000 Open source
20182018-06-30	Year over year	-6.9%	Revenue: 43710000 Open source Revenue: 46954000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2016-06-30	Operating margin	Not reported	Revenue: 42214000 Open source
2017-03-31	Operating margin	Not reported	Revenue: 35707000 Open source
2017-06-30	Operating margin	Not reported	Revenue: 46954000 Open source
2018-03-31	Operating margin	Not reported	Revenue: 31145000 Open source
2018-06-30	Operating margin	Not reported	Revenue: 43710000 Open source
2016-06-30	Net margin	Not reported	Revenue: 42214000 Open source
2017-03-31	Net margin	Not reported	Revenue: 35707000 Open source
2017-06-30	Net margin	Not reported	Revenue: 46954000 Open source
2018-03-31	Net margin	Not reported	Revenue: 31145000 Open source
2018-06-30	Net margin	Not reported	Revenue: 43710000 Open source
20162016-06-30	Free cash flow margin	Not reported	Revenue: 42214000 Open source
20172017-03-31	Free cash flow margin	Not reported	Revenue: 35707000 Open source
20172017-06-30	Free cash flow margin	Not reported	Revenue: 46954000 Open source
20182018-03-31	Free cash flow margin	Not reported	Revenue: 31145000 Open source
20182018-06-30	Free cash flow margin	Not reported	Revenue: 43710000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(iso4217-usd)	Source evidence
20162016-06-30	Operating cash flow	Not reported	No source recorded
20172017-03-31	Operating cash flow	Not reported	No source recorded
20172017-06-30	Operating cash flow	Not reported	No source recorded
20182018-03-31	Operating cash flow	Not reported	No source recorded
20182018-06-30	Operating cash flow	Not reported	No source recorded

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value	Source evidence
20162016-06-30	Free cash flow	Unavailable	No source recorded
20172017-03-31	Free cash flow	Unavailable	No source recorded
20172017-06-30	Free cash flow	Unavailable	No source recorded
20182018-03-31	Free cash flow	Unavailable	No source recorded
20182018-06-30	Free cash flow	Unavailable	No source recorded

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2016-06-30	Liabilities / assets	Not reported	No source recorded
2017-03-31	Liabilities / assets	Not reported	No source recorded
2017-06-30	Liabilities / assets	Not reported	No source recorded
2018-03-31	Liabilities / assets	Not reported	No source recorded
2018-06-30	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2016-06-30	Current assets / current liabilities	Not reported	No source recorded
2017-03-31	Current assets / current liabilities	Not reported	No source recorded
2017-06-30	Current assets / current liabilities	Not reported	No source recorded
2018-03-31	Current assets / current liabilities	Not reported	No source recorded
2018-06-30	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2021 2020-07-01 – 2021-06-30	USD 8.01 million Exact value Exact value: 8013000 USD 2020-07-01 – 2021-06-30: 8013000 USD Inspect Net Income Open source Share or cite Citation for Net Income · INTEGRATED BIOPHARMA INC · 2021-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Net Income: 8013000 USD Concept: fundies:NetIncome Period: 2020-07-01 to 2021-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504/explain?concept=fundies%3ANetIncome&period=2021-06-30&surface=latest&period_type=duration&start=2020-07-01&unit=USD&dimensions= Input fundies:NetIncome: 8013000 USD (2020-07-01 to 2021-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774922022334/inbp20220630_10k.htm#645049 Filing: 000143774922022334 The citation records this snapshot. The page link may show a newer release later.	USD 3.05 million Exact value Exact value: 3050000 USD 2020-07-01 – 2021-06-30: 3050000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INTEGRATED BIOPHARMA INC · 2021-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Operating Cash Flow: 3050000 USD Concept: fundies:OperatingCashFlow Period: 2020-07-01 to 2021-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504/explain?concept=fundies%3AOperatingCashFlow&period=2021-06-30&surface=latest&period_type=duration&start=2020-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 3050000 USD (2020-07-01 to 2021-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774922022334/inbp20220630_10k.htm#676359 Filing: 000143774922022334 The citation records this snapshot. The page link may show a newer release later.	USD 295,000 Exact value Exact value: 295000 USD 2020-07-01 – 2021-06-30: 295000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INTEGRATED BIOPHARMA INC · 2021-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Capital Expenditure: 295000 USD Concept: fundies:CapitalExpenditure Period: 2020-07-01 to 2021-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504/explain?concept=fundies%3ACapitalExpenditure&period=2021-06-30&surface=latest&period_type=duration&start=2020-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 295000 USD (2020-07-01 to 2021-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774922022334/inbp20220630_10k.htm#679187 Filing: 000143774922022334 The citation records this snapshot. The page link may show a newer release later.	USD 2.76 million Calculation and evidence 3050000 − 295000 USD Exact free cash flow: 2755000 USD 2020-07-01 – 2021-06-30: 3050000 USD · Inspect Operating Cash Flow · Source 2020-07-01 – 2021-06-30: 295000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INTEGRATED BIOPHARMA INC · 2021-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Free cash flow: 2755000 USD Concept: free-cash-flow Period: 2020-07-01 to 2021-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 3050000 USD (2020-07-01 to 2021-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774922022334/inbp20220630_10k.htm#676359 Filing: 000143774922022334 Input fundies:CapitalExpenditure: 295000 USD (2020-07-01 to 2021-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774922022334/inbp20220630_10k.htm#679187 Filing: 000143774922022334 The citation records this snapshot. The page link may show a newer release later.
2022 2021-07-01 – 2022-06-30	USD 3.84 million Exact value Exact value: 3838000 USD 2021-07-01 – 2022-06-30: 3838000 USD Inspect Net Income Open source Share or cite Citation for Net Income · INTEGRATED BIOPHARMA INC · 2022-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Net Income: 3838000 USD Concept: fundies:NetIncome Period: 2021-07-01 to 2022-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504/explain?concept=fundies%3ANetIncome&period=2022-06-30&surface=latest&period_type=duration&start=2021-07-01&unit=USD&dimensions= Input fundies:NetIncome: 3838000 USD (2021-07-01 to 2022-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774923026022/inbp20230630_10k.htm#628547 Filing: 000143774923026022 The citation records this snapshot. The page link may show a newer release later.	USD 4.09 million Exact value Exact value: 4091000 USD 2021-07-01 – 2022-06-30: 4091000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INTEGRATED BIOPHARMA INC · 2022-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Operating Cash Flow: 4091000 USD Concept: fundies:OperatingCashFlow Period: 2021-07-01 to 2022-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504/explain?concept=fundies%3AOperatingCashFlow&period=2022-06-30&surface=latest&period_type=duration&start=2021-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 4091000 USD (2021-07-01 to 2022-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774923026022/inbp20230630_10k.htm#659464 Filing: 000143774923026022 The citation records this snapshot. The page link may show a newer release later.	USD 486,000 Exact value Exact value: 486000 USD 2021-07-01 – 2022-06-30: 486000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INTEGRATED BIOPHARMA INC · 2022-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Capital Expenditure: 486000 USD Concept: fundies:CapitalExpenditure Period: 2021-07-01 to 2022-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504/explain?concept=fundies%3ACapitalExpenditure&period=2022-06-30&surface=latest&period_type=duration&start=2021-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 486000 USD (2021-07-01 to 2022-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774923026022/inbp20230630_10k.htm#662471 Filing: 000143774923026022 The citation records this snapshot. The page link may show a newer release later.	USD 3.61 million Calculation and evidence 4091000 − 486000 USD Exact free cash flow: 3605000 USD 2021-07-01 – 2022-06-30: 4091000 USD · Inspect Operating Cash Flow · Source 2021-07-01 – 2022-06-30: 486000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INTEGRATED BIOPHARMA INC · 2022-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Free cash flow: 3605000 USD Concept: free-cash-flow Period: 2021-07-01 to 2022-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 4091000 USD (2021-07-01 to 2022-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774923026022/inbp20230630_10k.htm#659464 Filing: 000143774923026022 Input fundies:CapitalExpenditure: 486000 USD (2021-07-01 to 2022-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774923026022/inbp20230630_10k.htm#662471 Filing: 000143774923026022 The citation records this snapshot. The page link may show a newer release later.
2023 2022-07-01 – 2023-06-30	−USD 34,000 Exact value Exact value: -34000 USD 2022-07-01 – 2023-06-30: -34000 USD Inspect Net Income Open source Share or cite Citation for Net Income · INTEGRATED BIOPHARMA INC · 2023-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Net Income: -34000 USD Concept: fundies:NetIncome Period: 2022-07-01 to 2023-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504/explain?concept=fundies%3ANetIncome&period=2023-06-30&surface=latest&period_type=duration&start=2022-07-01&unit=USD&dimensions= Input fundies:NetIncome: -34000 USD (2022-07-01 to 2023-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774924029768/inbp20240630_10k.htm#625450 Filing: 000143774924029768 The citation records this snapshot. The page link may show a newer release later.	USD 1.23 million Exact value Exact value: 1232000 USD 2022-07-01 – 2023-06-30: 1232000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INTEGRATED BIOPHARMA INC · 2023-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Operating Cash Flow: 1232000 USD Concept: fundies:OperatingCashFlow Period: 2022-07-01 to 2023-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504/explain?concept=fundies%3AOperatingCashFlow&period=2023-06-30&surface=latest&period_type=duration&start=2022-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 1232000 USD (2022-07-01 to 2023-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774924029768/inbp20240630_10k.htm#655008 Filing: 000143774924029768 The citation records this snapshot. The page link may show a newer release later.	USD 116,000 Exact value Exact value: 116000 USD 2022-07-01 – 2023-06-30: 116000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INTEGRATED BIOPHARMA INC · 2023-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Capital Expenditure: 116000 USD Concept: fundies:CapitalExpenditure Period: 2022-07-01 to 2023-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504/explain?concept=fundies%3ACapitalExpenditure&period=2023-06-30&surface=latest&period_type=duration&start=2022-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 116000 USD (2022-07-01 to 2023-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774924029768/inbp20240630_10k.htm#657794 Filing: 000143774924029768 The citation records this snapshot. The page link may show a newer release later.	USD 1.12 million Calculation and evidence 1232000 − 116000 USD Exact free cash flow: 1116000 USD 2022-07-01 – 2023-06-30: 1232000 USD · Inspect Operating Cash Flow · Source 2022-07-01 – 2023-06-30: 116000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INTEGRATED BIOPHARMA INC · 2023-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Free cash flow: 1116000 USD Concept: free-cash-flow Period: 2022-07-01 to 2023-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 1232000 USD (2022-07-01 to 2023-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774924029768/inbp20240630_10k.htm#655008 Filing: 000143774924029768 Input fundies:CapitalExpenditure: 116000 USD (2022-07-01 to 2023-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774924029768/inbp20240630_10k.htm#657794 Filing: 000143774924029768 The citation records this snapshot. The page link may show a newer release later.
2024 2023-07-01 – 2024-06-30	USD 112,000 Exact value Exact value: 112000 USD 2023-07-01 – 2024-06-30: 112000 USD Inspect Net Income Open source Share or cite Citation for Net Income · INTEGRATED BIOPHARMA INC · 2024-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Net Income: 112000 USD Concept: fundies:NetIncome Period: 2023-07-01 to 2024-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504/explain?concept=fundies%3ANetIncome&period=2024-06-30&surface=latest&period_type=duration&start=2023-07-01&unit=USD&dimensions= Input fundies:NetIncome: 112000 USD (2023-07-01 to 2024-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774925029711/inbp20250630_10k.htm#657835 Filing: 000143774925029711 The citation records this snapshot. The page link may show a newer release later.	USD 943,000 Exact value Exact value: 943000 USD 2023-07-01 – 2024-06-30: 943000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INTEGRATED BIOPHARMA INC · 2024-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Operating Cash Flow: 943000 USD Concept: fundies:OperatingCashFlow Period: 2023-07-01 to 2024-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504/explain?concept=fundies%3AOperatingCashFlow&period=2024-06-30&surface=latest&period_type=duration&start=2023-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 943000 USD (2023-07-01 to 2024-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774925029711/inbp20250630_10k.htm#689818 Filing: 000143774925029711 The citation records this snapshot. The page link may show a newer release later.	USD 553,000 Exact value Exact value: 553000 USD 2023-07-01 – 2024-06-30: 553000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INTEGRATED BIOPHARMA INC · 2024-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Capital Expenditure: 553000 USD Concept: fundies:CapitalExpenditure Period: 2023-07-01 to 2024-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504/explain?concept=fundies%3ACapitalExpenditure&period=2024-06-30&surface=latest&period_type=duration&start=2023-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 553000 USD (2023-07-01 to 2024-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774925029711/inbp20250630_10k.htm#693866 Filing: 000143774925029711 The citation records this snapshot. The page link may show a newer release later.	USD 390,000 Calculation and evidence 943000 − 553000 USD Exact free cash flow: 390000 USD 2023-07-01 – 2024-06-30: 943000 USD · Inspect Operating Cash Flow · Source 2023-07-01 – 2024-06-30: 553000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INTEGRATED BIOPHARMA INC · 2024-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Free cash flow: 390000 USD Concept: free-cash-flow Period: 2023-07-01 to 2024-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 943000 USD (2023-07-01 to 2024-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774925029711/inbp20250630_10k.htm#689818 Filing: 000143774925029711 Input fundies:CapitalExpenditure: 553000 USD (2023-07-01 to 2024-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774925029711/inbp20250630_10k.htm#693866 Filing: 000143774925029711 The citation records this snapshot. The page link may show a newer release later.
2025 2024-07-01 – 2025-06-30	USD 808,000 Exact value Exact value: 808000 USD 2024-07-01 – 2025-06-30: 808000 USD Inspect Net Income Open source Share or cite Citation for Net Income · INTEGRATED BIOPHARMA INC · 2025-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Net Income: 808000 USD Concept: fundies:NetIncome Period: 2024-07-01 to 2025-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504/explain?concept=fundies%3ANetIncome&period=2025-06-30&surface=latest&period_type=duration&start=2024-07-01&unit=USD&dimensions= Input fundies:NetIncome: 808000 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm#624774 Filing: 000143774926031241 The citation records this snapshot. The page link may show a newer release later.	USD 2.07 million Exact value Exact value: 2065000 USD 2024-07-01 – 2025-06-30: 2065000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INTEGRATED BIOPHARMA INC · 2025-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Operating Cash Flow: 2065000 USD Concept: fundies:OperatingCashFlow Period: 2024-07-01 to 2025-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504/explain?concept=fundies%3AOperatingCashFlow&period=2025-06-30&surface=latest&period_type=duration&start=2024-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 2065000 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm#656770 Filing: 000143774926031241 The citation records this snapshot. The page link may show a newer release later.	USD 191,000 Exact value Exact value: 191000 USD 2024-07-01 – 2025-06-30: 191000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INTEGRATED BIOPHARMA INC · 2025-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Capital Expenditure: 191000 USD Concept: fundies:CapitalExpenditure Period: 2024-07-01 to 2025-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504/explain?concept=fundies%3ACapitalExpenditure&period=2025-06-30&surface=latest&period_type=duration&start=2024-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 191000 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm#660820 Filing: 000143774926031241 The citation records this snapshot. The page link may show a newer release later.	USD 1.87 million Calculation and evidence 2065000 − 191000 USD Exact free cash flow: 1874000 USD 2024-07-01 – 2025-06-30: 2065000 USD · Inspect Operating Cash Flow · Source 2024-07-01 – 2025-06-30: 191000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INTEGRATED BIOPHARMA INC · 2025-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Free cash flow: 1874000 USD Concept: free-cash-flow Period: 2024-07-01 to 2025-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 2065000 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm#656770 Filing: 000143774926031241 Input fundies:CapitalExpenditure: 191000 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm#660820 Filing: 000143774926031241 The citation records this snapshot. The page link may show a newer release later.
2026 2025-07-01 – 2026-06-30	−USD 2.84 million Exact value Exact value: -2842000 USD 2025-07-01 – 2026-06-30: -2842000 USD Inspect Net Income Open source Share or cite Citation for Net Income · INTEGRATED BIOPHARMA INC · 2026-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Net Income: -2842000 USD Concept: fundies:NetIncome Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504/explain?concept=fundies%3ANetIncome&period=2026-06-30&surface=latest&period_type=duration&start=2025-07-01&unit=USD&dimensions= Input fundies:NetIncome: -2842000 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm#624092 Filing: 000143774926031241 The citation records this snapshot. The page link may show a newer release later.	USD 1.24 million Exact value Exact value: 1241000 USD 2025-07-01 – 2026-06-30: 1241000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INTEGRATED BIOPHARMA INC · 2026-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Operating Cash Flow: 1241000 USD Concept: fundies:OperatingCashFlow Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504/explain?concept=fundies%3AOperatingCashFlow&period=2026-06-30&surface=latest&period_type=duration&start=2025-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 1241000 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm#655977 Filing: 000143774926031241 The citation records this snapshot. The page link may show a newer release later.	USD 346,000 Exact value Exact value: 346000 USD 2025-07-01 – 2026-06-30: 346000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INTEGRATED BIOPHARMA INC · 2026-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Capital Expenditure: 346000 USD Concept: fundies:CapitalExpenditure Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504/explain?concept=fundies%3ACapitalExpenditure&period=2026-06-30&surface=latest&period_type=duration&start=2025-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 346000 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm#660132 Filing: 000143774926031241 The citation records this snapshot. The page link may show a newer release later.	USD 895,000 Calculation and evidence 1241000 − 346000 USD Exact free cash flow: 895000 USD 2025-07-01 – 2026-06-30: 1241000 USD · Inspect Operating Cash Flow · Source 2025-07-01 – 2026-06-30: 346000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INTEGRATED BIOPHARMA INC · 2026-06-30 INTEGRATED BIOPHARMA INC (edgar:1016504) Free cash flow: 895000 USD Concept: free-cash-flow Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T22:59:20Z Snapshot: 362b78c88b25605ebbf5f8193ce288c9a3f3397857f197c90083b1803634d501 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016504?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 1241000 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm#655977 Filing: 000143774926031241 Input fundies:CapitalExpenditure: 346000 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm#660132 Filing: 000143774926031241 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

130 filings · 6,362 latest values · 6,362 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001016504, 1016504, INBP, edgar:1016504, inbp

Also known as CHEM INTERNATIONAL INC, INTEGRATED BIOPHARMA INC, INTEGRATED BIOPHARMA, INC., INTEGRATED HEALTH TECHNOLOGIES INC

INTEGRATED BIOPHARMA INC

Latest quarter

Revenue

Reported share-count change

Trailing twelve months

Revenue

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2018 2017-07-01 – 2018-06-30

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation